Abstract
There is a close correlation between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) in the course of pathophysiological processes. The neuroprotective action of glucagon-like peptide 1 (GLP-1), a latest drug for clinical treatment of T2DM, is being more deeply investigated at present, and a novel therapeutic strategy for AD with GLP-1 has been proposed boldly. This review mainly discussed the correlation of pathogenesis between T2DM and AD, the synthesis and secretion of GLP-1, the distribution and physiological effects of GLP-1 receptor in the brain, and the progresses on the study of GLP-1 in the treatment of AD.
Publication types
-
English Abstract
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / physiopathology*
-
Amyloid beta-Peptides / drug effects*
-
Amyloid beta-Peptides / metabolism
-
Animals
-
Brain / metabolism
-
Diabetes Mellitus, Type 2 / physiopathology
-
Glucagon-Like Peptide 1 / pharmacology
-
Glucagon-Like Peptide 1 / therapeutic use*
-
Glucagon-Like Peptide-1 Receptor
-
Humans
-
Neuroprotective Agents / pharmacology
-
Neuroprotective Agents / therapeutic use*
-
Receptors, Glucagon / metabolism
Substances
-
Amyloid beta-Peptides
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Neuroprotective Agents
-
Receptors, Glucagon
-
Glucagon-Like Peptide 1